 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.001.102  |
| Chemical and physical data | |
| Formula | C10H21N |
| Molar mass | 155.285 g·mol−1 |
| 3D model (JSmol) | |
| |
Pempidine is a ganglion-blocking drug, first reported in 1958 by two research groups working independently, and introduced as an oral treatment for hypertension.[1]
Reports on the "classical" pharmacology of pempidine have been published.[2][3] The Spinks group, at ICI, compared pempidine, its N-ethyl analogue, and mecamylamine in considerable detail, with additional data related to several structurally simpler compounds.[2]
LD50 for the HCl salt of pempidine in mice: 74 mg/kg (intravenous); 125 mg/kg (intraperitoneal); 413 mg/kg (oral).[2]
Pempidine is an aliphatic, sterically hindered, cyclic, tertiary amine, which is a weak base: in its protonated form it has a pKa of 11.25.[4]
Pempidine is a liquid with a boiling point of 187–188 °C and a density of 0.858 g/cm3.[2]
Two early syntheses of this compound are those of Leonard and Hauck,[5] and Hall.[4] These are very similar in principle: Leonard and Hauck reacted phorone with ammonia, to produce 2,2,6,6-tetramethyl-4-piperidone, which was then reduced by means of the Wolff–Kishner reductionto2,2,6,6-tetramethylpiperidine. This secondary amine was then N-methylated using methyl iodide and potassium carbonate.[6]
Hall's method involved reacting acetone with ammonia in the presence of calcium chloride to give 2,2,6,6-tetramethyl-4-piperidone, which was then reduced under Wolff–Kishner conditions, followed by N-methylation of the resulting 2,2,6,6-tetramethylpiperidine with methyl p-toluenesulfonate.
|
| |||||
|---|---|---|---|---|---|
| Sympatholytics (antagonize α-adrenergic vasoconstriction) |
| ||||
| Other antagonists |
| ||||
| |||||
|
| |||||
|---|---|---|---|---|---|
| nAChRsTooltip Nicotinic acetylcholine receptors |
| ||||
| Precursors (and prodrugs) |
| ||||
| |||||
